Angiotensin II receptor blocker telmisartan attenuates aortic stiffening and remodelling in STZ-diabetic rats

Diabetology and Metabolic Syndrome

Volumn 6, Issue 1, 2014, Pages

  Salum, Erik ^a,b   Butlin, Mark ^c   Kals, Jaak ^a,b,d   Zilmer, Mihkel ^a,b   Eha, Jaan ^a   Avolio, Alberto P ^c   Arend, Andres ^a   Aunapuu, Marina ^a,e   Kampus, Priit ^a,b  

^a UNIVERSITY OF TARTU   (Estonia)

^b Faculty of Medicine   (Estonia)

^c MACQUARIE UNIVERSITY   (Australia)

^d TARTU UNIVERSITY HOSPITAL   (Estonia)

^e ESTONIAN UNIVERSITY OF LIFE SCIENCES   (Estonia)

Author keywords

Arterial stiffness; Collagen; Diabetes; Elastin; Pulse wave velocity; Streptozotocin; Telmisartan

Indexed keywords

COLLAGEN FIBER; ELASTIN; GLUCOSE; GLYCERYL TRINITRATE; PHENYLEPHRINE; STREPTOZOCIN; TELMISARTAN;

ADVENTITIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA DISEASE; AORTA MEDIA; AORTA WALL; AORTIC REMODELLING; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CELL NUCLEUS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; GLUCOSE URINE LEVEL; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HEMODYNAMICS; HYPERPHAGIA; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INSULIN DEPENDENT DIABETES MELLITUS; INTIMA; MALE; MEAN ARTERIAL PRESSURE; MORPHOMETRICS; NONHUMAN; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PULSE WAVE; RAT; SMOOTH MUSCLE FIBER; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; SYSTOLIC BLOOD PRESSURE;

EID: 84901689507     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-6-57     Document Type: Article

References (42)

1. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Stamler J, Vaccaro O, Neaton JD, Wentworth D, Diabetes Care 1993 16 434 444 10.2337/diacare.16.2.434 8432214 (Pubitemid 23046633)
2. Progression of large artery structural and functional alterations in Type I diabetes. Giannattasio C, Failla M, Grappiolo A, Gamba PL, Paleari F, Mancia G, Diabetologia 2001 44 203 208 10.1007/s001250051600 11270677 (Pubitemid 32156205)
3. Diminished arterial elasticity in diabetes: association with fluorescent advanced glycosylation end products in collagen. Airaksinen KE, Salmela PI, Linnaluoto MK, Ikaheimo MJ, Ahola K, Ryhanen LJ, Cardiovasc Res 1993 27 942 945 10.1093/cvr/27.6.942 8221782 (Pubitemid 23219508)
4. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Mattace-Raso FU, van der Cammen TJ, Hofman A, van Popele NM, Bos ML, Schalekamp MA, Asmar R, Reneman RS, Hoeks AP, Breteler MM, Witteman JC, Circulation 2006 113 657 663 10.1161/CIRCULATIONAHA.105.555235 16461838
5. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, Ducimetiere P, Benetos A, Hypertension 2001 37 1236 1241 10.1161/01.HYP.37.5.1236 11358934 (Pubitemid 34163575)
6. Impact of aortic stiffness on survival in end-stage renal disease. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM, Circulation 1999 99 2434 2439 10.1161/01.CIR.99.18.2434 10318666 (Pubitemid 29218240)
7. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG, Circulation 2002 106 2085 2090 10.1161/01.CIR.0000033824.02722.F7 12379578 (Pubitemid 35192814)
8. Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. Dzau VJ, Gibbons GH, Pratt RE, Hypertension 1991 18 100 105
9. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Griffin SA, Brown WC, MacPherson F, McGrath JC, Wilson VG, Korsgaard N, Mulvany MJ, Lever AF, Hypertension 1991 17 626 635 10.1161/01.HYP.17.5.626 2022407
10. Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus. Miller JA, J Am Soc Nephrol 1999 10 1778 1785 10446946 (Pubitemid 29364677)
11. Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. Prospective UK, BMJ 1998 317 713 720 10.1136/bmj.317.7160.713 9732338
12. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators, N Engl J Med 2001 345 861 869 10.1056/NEJMoa011161 11565518
13. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy, Heart Outcomes Prevention Evaluation Study Investigators. Heart Outcomes Prevention Evaluation Study Investigators, Lancet 2000 355 253 259 10675071
14. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S, LIFE Study Group, Lancet 2002 359 1004 1010 10.1016/S0140- 6736(02)08090-X 11937179 (Pubitemid 34286537)
15. Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease. Pershadsingh HA, Kurtz TW, Diabetes Care 2004 27 1015 15047668 (Pubitemid 38420234)
16. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R, Hypertens Res 2004 27 457 464 10.1291/hypres.27.457 15302981 (Pubitemid 39157547)
17. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Yamagishi S, Takeuchi M, Med Hypotheses 2005 64 476 478 10.1016/j.mehy.2004.09.015 15617852 (Pubitemid 40023005)
18. Effect of vitamin D on aortic remodeling in streptozotocin-induced diabetes. Salum E, Kampus P, Zilmer M, Eha J, Butlin M, Avolio AP, Põdramägi T, Arend A, Aunapuu M, Kals J, Cardiovasc Diabetol 2012 11 58 10.1186/1475-2840-11-58 22631050
19. Aortic stiffness is associated with vascular calcification and remodeling in a chronic kidney disease rat model. Ng K, Hildreth CM, Phillips JK, Avolio AP, Am J Physiol Renal Physiol 2011 300 1431 1436 10.1152/ajprenal.00079.2011
20. More regression methods. Wilcox RR, Introduction to robust estimation and hypothesis testing Burlington, MA, USA: Elsevier Academic Press 2 2005
21. Effects of streptozotocin-induced diabetes on heart rate, blood pressure and cardiac autonomic nervous control. Hicks KK, Seifen E, Stimers JR, Kennedy RH, J Auton Nerv Syst 1998 69 21 30 10.1016/S0165-1838(98)00004-6 9672120 (Pubitemid 28270882)
22. Biomechanical and morphometric properties of the arterial wall referenced to the zero-stress state in experimental diabetes. Zhao JB, Lu X, Zhuang FY, Gregersen H, Biorheology 2000 37 385 400 11204544 (Pubitemid 32010106)
23. Effects of diabetes and gender on mechanical properties of the arterial system in rats: aortic impedance analysis. Chang KC, Hsu KL, Tseng YZ, Exp Biol Med (Maywood) 2003 228 70 78 12524476
24. Assessment of elastin and collagen contribution to aortic elasticity in conscious dogs. Armentano RL, Levenson J, Barra JG, Fischer EI, Breitbart GJ, Pichel RH, Simon A, Am J Physiol 1991 260 1870 1877
25. Effect of elastin degradation on carotid wall mechanics as assessed by a constituent-based biomechanical model. Fonck E, Prod'hom G, Roy S, Augsburger L, Rufenacht DA, Stergiopulos N, Am J Physiol Heart Circ Physiol 2007 292 2754 2763 10.1152/ajpheart.01108.2006 (Pubitemid 47084524)
26. The contribution of vascular smooth muscle, elastin and collagen on the passive mechanics of porcine carotid arteries. Kochova P, Kuncova J, Sviglerova J, Cimrman R, Miklikova M, Liska V, Tonar Z, Physiol Meas 2012 33 1335 1351 10.1088/0967-3334/33/8/1335 22813960
27. Determinants of carotid artery wall thickening in young patients with Type 1 diabetes mellitus. Frost D, Beischer W, Diabet Med 1998 15 851 857 10.1002/(SICI)1096-9136(199810)15:10<851::AID-DIA660>3.0.CO;2-9 9796886 (Pubitemid 28451955)
28. Atherosclerosis in carotid artery of young IDDM patients monitored by ultrasound high-resolution B-mode imaging. Yamasaki Y, Kawamori R, Matsushima H, Nishizawa H, Kodama M, Kajimoto Y, Morishima T, Kamada T, Diabetes 1994 43 634 639 10.2337/diab.43.5.634 8168638 (Pubitemid 24138774)
29. Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, et al. Eur Heart J 2007 2007 28 1462 1536
30. Time-dependent alterations in rat macrovessels with type 1 diabetes. Searls Y, Smirnova IV, Vanhoose L, Fegley B, Loganathan R, Stehno-Bittel L, Exp Diabetes Res 2012 2012 278620 22315586
31. Vanadyl sulfate protects against streptozotocin-induced morphological and biochemical changes in rat aorta. Akgün-Dar K, Bolkent S, Yanardag R, Tunali S, Cell Biochem Funct 2007 25 603 609 10.1002/cbf.1354 16892454 (Pubitemid 351202345)
32. Endothelin-mediated remodeling in aortas of diabetic rats. Fukuda G, Khan ZA, Barbin YP, Farhangkhoee H, Tilton RG, Chakrabarti S, Diabetes Metab Res Rev 2005 21 367 375 10.1002/dmrr.527 15580650 (Pubitemid 40945959)
33. Type-2 diabetes-induced changes in vascular extracellular matrix gene expression: relation to vessel size. Song W, Ergul A, Cardiovasc Diabetol 2006 5 3 10.1186/1475-2840-5-3 16503991
34. Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products. Rumble JR, Cooper ME, Soulis T, Cox A, Wu L, Youssef S, Jasik M, Jerums G, Gilbert RE, J Clin Invest 1997 99 1016 1027 10.1172/JCI119229 9062360 (Pubitemid 27123639)
35. Transforming growth factor-beta receptor and fibronectin expressions in aortic smooth muscle cells in diabetic rats. Kanzaki T, Shiina R, Saito Y, Zardi L, Morisaki N, Diabetologia 1997 40 383 391 10.1007/s001250050691 9112014 (Pubitemid 27132608)
36. Vitamin D reduces deposition of advanced glycation end-products in the aortic wall and systemic oxidative stress in diabetic rats. Salum E, Kals J, Kampus P, Salum T, Zilmer K, Aunapuu M, Arend A, Eha J, Zilmer M, Diabetes Res Clin Pract 2013 100 243 249 10.1016/j.diabres.2013.03.008 23522919
37. N epsilon-(carboxymethyl) lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW, Biochemistry 1995 34 10872 10878 10.1021/bi00034a021 7662668
38. Effects of AT1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain. Wagner J, Drab M, Bohlender J, Amann K, Wienen W, Ganten D, Clin Exp Hypertens 1998 20 205 221 10.3109/10641969809053215 9533614 (Pubitemid 28160942)
39. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW, Hypertension 2004 43 993 1002 10.1161/01.HYP.0000123072.34629.57 15007034 (Pubitemid 38579904)
40. Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases. Takano H, Hasegawa H, Zou Y, Komuro I, Curr Pharm Des 2004 10 2779 2786 10.2174/1381612043383719 15320743 (Pubitemid 39137176)
41. Peroxisome Proliferator-Activated Receptors and Atherogenesis: Regulators of Gene Expression in Vascular Cells. Marx N, Duez H, Fruchart J-C, Staels B, Circ Res 2004 94 1168 1178 10.1161/01.RES.0000127122.22685.0A 15142970 (Pubitemid 38656403)
42. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. Miyata T, Van Ypersele De Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, Ishikawa N, Nangaku M, Kurokawa K, J Am Soc Nephrol 2002 13 2478 2487 10.1097/01.ASN.0000032418.67267.F2 12239236